Literature DB >> 12556689

Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.

Santiago Pérez-Hoyos1, Julia del Amo, Roberto Muga, Jorge del Romero, Patricia García de Olalla, Rafael Guerrero, Ildefonso Hernàndez-Aguado.   

Abstract

OBJECTIVE: To evaluate the population effectiveness of highly active antiretroviral therapy (HAART) in HIV progression and determine the heterogeneity of the effect of HAART in GEMES (Spanish multicenter study of seroconverters).
DESIGN: Multicenter cohort study.
METHODS: Data from 1091 persons with well-documented HIV seroconversion dates from 1980s to January 2000 were analysed. Risk of AIDS and death in subjects with same duration of HIV infection were compared in different calendar periods; before 1992, 1992-1995 (reference), 1996-1997, 1998 and 1999 with Kaplan-Meier methods and Cox proportional hazards models, allowing for late entry, fitting calendar period as time-dependent covariate and adjusting for transmission category, age and gender.
RESULTS: Statistically significant reductions in the risk of AIDS were first observed in 1998 [hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.35-1.01] becoming more pronounced in 1999 (HR, 0.45; 95% CI, 0.24-0.84). Reduction in the risk of death was seen in 1997, though only reached borderline significance in 1999 (HR, 0.53; 95% CI, 0.26-1.07). Progression to AIDS and death was slower in women (HR, 0.68; 95% CI, 0.46-0.99 and HR, 0.53; 95% CI, 0.33-0.87, respectively). Compared with men who have sex with men (MSM), intravenous drug users (IDU) had lower reductions in the risk of AIDS and death.
CONCLUSIONS: Reductions in incidence of AIDS and death in GEMES are seen after 1998 and 1999, respectively, compared with 1992-1995, being more pronounced in MSM compared with IDU, the commonest category in Spain.

Entities:  

Mesh:

Year:  2003        PMID: 12556689     DOI: 10.1097/00002030-200302140-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  29 in total

Review 1.  Multiple sclerosis-like illness in a HIV-1 patient.

Authors:  Eduardo Durán; Juan Gálvez; Giorgio Patrignani; Guillermo Izquierdo
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy.

Authors:  Michael J Silverberg; Lisa P Jacobson; Audrey L French; Mallory D Witt; Stephen J Gange
Journal:  J Pain Symptom Manage       Date:  2009-03-28       Impact factor: 3.612

3.  Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi.

Authors:  Katie Taylor-Smith; Hannock Tweya; Anthony Harries; Erik Schoutene; Andreas Jahn
Journal:  Malawi Med J       Date:  2010-06       Impact factor: 0.875

4.  Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma.

Authors:  Joseph B Babigumira; Solomon J Lubinga; Emma Castro; Brian Custer
Journal:  Blood Transfus       Date:  2016-11-16       Impact factor: 3.443

5.  Do HIV disease progression and HAART response vary among injecting drug users in Europe?

Authors:  Liselotte van Asten; Robert Zangerle; Ildefonso Hernández Aguado; Faroudy Boufassa; Barbara Broers; Raymond P Brettle; J Roy Robertson; Jim McMenamin; Roel A Coutinho; Maria Prins
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

6.  The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting.

Authors:  Alana T Brennan; Mhairi Maskew; Ian Sanne; Matthew P Fox
Journal:  Trop Med Int Health       Date:  2013-02-18       Impact factor: 2.622

7.  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

Authors:  Maile Ray; Roger Logan; Jonathan A C Sterne; Sonia Hernández-Díaz; James M Robins; Caroline Sabin; Loveleen Bansi; Ard van Sighem; Frank de Wolf; Dominique Costagliola; Emilie Lanoy; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casbona; Julia del Amo; Santiago Moreno; Amy Justice; Joseph Goulet; Sara Lodi; Andrew Phillips; Rémonie Seng; Laurence Meyer; Santiago Pérez-Hoyos; Patricia García de Olalla; Miguel A Hernán
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

8.  Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment.

Authors:  Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate
Journal:  Drug Alcohol Depend       Date:  2019-09-04       Impact factor: 4.492

9.  HIV disease progression to CD4 count <200 cells/μL and death in Saskatoon, Saskatchewan.

Authors:  Stephanie Konrad; Stuart Skinner; Germain Bukassa Kazadi; Kali Gartner; Hyun June Lim
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

10.  The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.

Authors:  E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.